Objectives Methylphenidate (MPH) treatment in patients with attention-deficit/hyperactivity
disorder (ADHD) is reported to reduce the risk for injuries. In the present study, the rate and …

Objectives: The aim of this study was to assess whether once-daily Concerta®
extendedrelease (XR) methylphenidate (MPH) is associated with:(1) better compliance;(2) …

Objectives: The purpose of this study was to identify the optimal dose of osmotic release oral
system methylphenidate (OROS-MPH) using a dosage forced-titration scheme to achieve …

Objective: The purpose of this study was to assess the time of onset and time course of
efficacy over 12.0 hours of extended-release multilayer bead formulation of methylphenidate …

Objective: To examine the efficacy, safety, and tolerability of methylphenidate extended-
release orally disintegrating tablets (MPH XR-ODT) for the treatment of attention …

Objective. A new once-a-day methylphenidate (MPH) formulation, Concerta
(methylphenidate HCl) extended-release tablets (OROS MPH), has been developed. This …

Objective: To determine the pharmacokinetic (PK) profile of a proprietary formulation of
methylphenidate (MPH) in children and adolescents with attention-deficit/hyperactivity …

Objective: The purpose of this study was to evaluate the comparative efficacy and safety of a
novel long-duration multilayer-release (MLR) methylphenidate (MPH) formulation and …

Objective To compare the continuity of methylphenidate hydrochloride (MPH) therapy
among youth Medicaid beneficiaries treated for attention-deficit/hyperactivity disorder with …

This study examined the efficacy and safety of osmotic release oral system methylphenidate
(OROS MPH) as compared with immediate-release MPH (IR MPH) in children with attention …